ICCC - ImmuCell preliminary Q2 revenue falls 9% Y/Y

2023-07-11 18:02:37 ET

• ImmuCell ( NASDAQ: ICCC ) on Tuesday announced preliminary Q2 sales that fell from a year ago.
• The company reported sales of $3.53M in Q2 2023, a 9% decrease from $3.86M in the same period last year.
• ICCC cited the lower sales to its previously disclosed production slowdown implemented during Q1 to remediate contamination events impacting the company's manufacturing process.
• "As of June 30, 2023, the backlog of orders was equal to approximately $8M, representing a significant increase from approximately $2.5M as of December 31, 2022," ICCC said in a statement .
• ImmuCell ( ICCC ) stock +1.8% to $5.07 after hours.

For further details see: